Sensitivity of Single-Molecule Array Assays for Detection of Clostridium difficile Toxins in Comparison to Conventional Laboratory Testing Algorithms

Alice Banz, Aude Lantz, Brigitte Riou, Agnès Foussadier, Mark Miller, Kerrie Davies, Mark Wilcox

bioMérieux, Marcy L’Etoile, France
Leeds Teaching Hospitals, Leeds, United Kingdom
University of Leeds, Leeds, United Kingdom

ABSTRACT Guidelines recommend the use of an algorithm for the laboratory diagnosis of Clostridium difficile infection (CDI). Enzyme immunoassays (EIAs) detecting C. difficile toxins cannot be used as standalone tests due to suboptimal sensitivity, and molecular tests suffer from nonspecificity by detecting colonization. Sensitive immunoassays have recently been developed to improve and simplify CDI diagnosis. Assays detecting CD toxins have been developed using single-molecule array (SIMOA) technology. SIMOA performance was assessed relative to a laboratory case definition of CDI defined by positive glutamate dehydrogenase (GDH) screen and cell cytolysin neutralizing assay (CCNA). Samples were tested with SIMOA assays and a commercial toxin EIA to compare performance, with discrepancy resolution using a commercial nucleic acid-based test and a second cell cytotoxicity assay. The SIMOA toxin A and toxin B assays showed limits of detection of 0.6 and 2.9 pg/ml, respectively, and intra-assay coefficients of variation of less than 10%. The optimal clinical thresholds for the toxin A and toxin B assays were determined to be 22.1 and 18.8 pg/ml, respectively, with resultant sensitivities of 84.8 and 95.5%. In contrast, a high-performing EIA toxin test had a sensitivity of 71.2%. Thus, the SIMOA assays detected toxins in 24% more samples with laboratory-defined CDI than the high-performing EIA (95% [63/66] versus 71% [47/66]). This study shows that SIMOA C. difficile toxin assays have a higher sensitivity than currently available toxin EIA and have the potential to improve CDI diagnosis.

KEYWORDS Clostridium difficile, ultrasensitivity

Clostridium difficile infection (CDI) is a gastrointestinal disease caused by the Gram-positive bacteria Clostridium difficile (CD). This pathogen is responsible for pseudomembranous colitis and almost a quarter of all antibiotic-associated diarrhea (1). CDI has been shown to be common, serious, and costly (2), with varied disease severity that is associated with strain virulence and patient risk factors (3–6).

Guidelines exist that provide recommendations on how to diagnose and treat CDI patients (7–10). Accurate diagnosis is essential to control endemic spread and outbreaks and to provide appropriate treatment to the patient (11). Diagnostic tests detect the bacteria, bacterial components such as glutamate dehydrogenase (GDH), the toxins responsible for the disease, or genetic components such as the toxin genes. The presence of C. difficile toxins in a diarrheal fecal specimen may be the most reliable indicator of true CDI (12). However, toxin testing by current enzyme immunoassays (EIAs) is not suitable as a standalone test due to their lack of sensitivity. There are several commercially available EIAs for toxin detection, but none of them are as sensitive as the gold-standard method, the cell cytolysin neutralizing assay (CCNA), which measures toxin B cytotoxic activity (13, 14). Nevertheless, most laboratories do
not perform the CCNA, as it is time consuming, requires cell-culture facilities and advanced technical skills, and has never been standardized. For these reasons, guidelines strongly recommend a two-stage testing approach (8, 10). This approach consists of the use of a highly sensitive assay with a high negative predictive value (thus ruling out CDI with a negative result), followed by secondary testing of positive specimens with an assay for the detection of C. difficile toxins. The highly sensitive assay recommended as a first step is either an EIA detecting GDH or a molecular assay detecting toxin genes. A positive result with molecular assay, if used as the only test for CDI, must be interpreted with caution, as it may be detecting carriage or colonization by a toxigenic strain in individuals who have diarrhea for other reasons (15). This is an important point to highlight, especially as the carriage rate can sometimes be quite high, up to 15% in adults (16, 17).

An automated one-step assay capable of detecting very small amounts of C. difficile toxins in a fecal sample could provide a significant improvement in the diagnosis of CDI. It has previously been shown that the single-molecule array (SIMOA) technology is able to detect a very low quantity of analyte in biological samples (18, 19). The development of sensitive assays by SIMOA for the detection of C. difficile A and B toxins in stool has shown promising results in comparison to toxigenic culture, CCNA, and molecular assay (20, 21). The objective of this study was to show that SIMOA toxin A and toxin B assays have a better analytical performance in comparison with one of the optimal EIAs currently available (13, 14).

MATERIALS AND METHODS

Clinical stool samples. Frozen stool samples from Canadian (Jewish General Hospital, Montreal, Canada) and French (Charcot private hospital, Sainte-Foy-lès-Lyon, France) hospitals were used to determine the limit of detection (LOD) and the reproducibility of the two SIMOA toxin assays. For sensitivity and specificity studies, clinical samples (n = 240) were collected at the Leeds Teaching Hospitals NHS Trust in 2014 (Leeds, United Kingdom), and kept at −80°C. These samples were characterized for CDI status using a laboratory case definition defined by positive GDH screen and CCNA toxin assay. Informed consent was not required for the use of anonymized residual diagnostic material, and appropriate ethical approval was granted for use of the samples from Leeds by the University of Leeds.

Sample preparation for SIMOA assays. Frozen stool samples were thawed, then homogenized using a plastic spatula, and 50 to 100 mg of sample were transferred into an Eppendorf tube. The exact quantity of stool was determined by weighing the tube, and the volume of sample diluent added was adjusted to achieve a final dilution of 1/21 (mg/ml). Sample diluent consisted in Tris-buffered saline (pH 7.4) containing detergent and preservative. The tube contents were mixed using a vortex and centrifuged at 3,000 × g for 10 min. The supernatant was collected and tested for toxins.

SIMOA toxin assays. The SIMOA toxin A and toxin B assays were manufactured with the same raw materials as those previously described (20, 21), except for calibrators, antitoxin A antibodies (Ab), and detector. We used native toxins A and B, purified from C. difficile strain VPI 10463, toxinotype 0 (Native Antigen Company, Oxfordshire, United Kingdom), as calibrators; anti-toxin A antibodies from bioMérieux (bioMérieux, Marcy l’Etoile, France); and detector antibody directly conjugated to the enzyme β-galactosidase (Roche Diagnostics Corporation, Indianapolis, IN). Both toxin A and toxin B assays were composed of paramagnetic beads (Quanterix Corporation, Lexington, MA) coated with Ab directed against toxin A or B and detectors specific for each toxin. Assays were performed on a SIMOA HD-1 Analyzer (Quanterix Corporation, Lexington, MA) located at bioMérieux in France. Supernatants of specimens were tested in duplicate in each SIMOA run along with calibrators and controls. The controls were positive and negative stool samples characterized by French hospitals.

Limits of detection (LOD) and limits of quantification (LOQ), repeatability, and reproducibility of SIMOA assays. Six runs were performed, one run per day, for six days. Each run was composed of eight calibrators in duplicate, two negative samples, and 20 positive stool samples in quadruplet. The limit of blank (LOB) was determined as the 99th percentile of the blank sample distribution and calculated nonparametrically on 60 values (two negative samples tested in quadruplet and one sample diluent tested in duplicate per run on six runs). LOD and LOQ of the assays were determined by using the precision profile method on the six lowest positive samples. The precision profile characterizes the relationship between the standard deviation (SD) and the toxin concentrations. The mathematical model is a second-order polynomial equation: $SD = a_0 + a_1 X + a_2 X^2$ with $a_0$, $a_1$, and $a_2$ corresponding to the parameters estimated for the second-order model and $X$ being the concentration at the LOD level. LOD was calculated as $LOD = LOB + Cp \cdot SD$, where $Cp$ is a corrector factor of the SD, taking into account the total number of samples ($N_{tot}$) and the number of replicates per sample ($K$),

$$Cp = \frac{1.645}{1 - \frac{1}{4KN_{tot} - K}}$$
C. sordelli (filtration of sample supernatant), the anti-toxin antibody (diluent used to dilute the stool sample (phosphate-buffered saline), the preparation of the sample and nonexistent at 0.02 pg/ml. Native purified toxin B the cytotoxic activity was high at 5 pg/ml, moderate at 1.5 pg/ml, low at 0.2 pg/ml, A at 250 pg/ml, moderate activity at 100 pg/ml, low activity at 20 pg/ml, and no activity at 10 pg/ml. For analytical sensitivity of the bMx CCNA assay, we have observed high cytotoxic activity using native toxin activity was caused by toxin B. The plate was examined at 24 and 48 h for cell rounding. In terms of Positive and negative controls (stool samples and media) were tested in parallel to the samples. A dilutions were done to achieve the following final dilutions: 1/120; 1/1,200; 1/12,000; and 1/120,000.

Comparison to a commercially available immunoassay. All samples were tested with the commercially available C. difficile Tox A/B II assay (Techlab, Blacksburg, VA), a fecal C. difficile toxin A and toxin B enzyme immunoassay, according to the manufacturer’s instructions. The C. difficile Tox A/B II assay was performed in parallel with the SIMOA assay, using the same aliquot. One-third of the samples had an additional freezing/thawing cycle before testing with the C. difficile Tox A/B II assay.

Toxin gene detection by molecular assay. The Xpert C. difficile assay (Cepheid Inc., Sunnyvale, CA) was performed using the Cepheid GeneXpert Systems. Sixty of the 96 GDH-positive CCNA-negative samples were tested with the Xpert C. difficile assay by the Leeds laboratory as part of an internal evaluation. At bioMérieux, the testing of the 36 GDH-positive CCNA-negative samples was completed, as well as additional testing for samples that gave discordant results between CCNA and the SIMOA assay.

Cell cytotoxicity neutralizing assay (CCNA). CCNA was performed at bioMérieux (bMx CCNA), on fecal samples that showed discordant results between the CCNA obtained by the Leeds laboratory and SIMOA, to verify that the toxin was present and functional in the samples. Vero cells (ATCC CCL-81) were inoculated at 30,000 cells/well on the day prior to the test. Samples were solubilized in minimum essential medium (MEM) with 1% fetal calf serum and 1% gentamicin, streptomycin, penicillin, and amphotericin B (Thermo Fisher Scientific, Waltham, MA) at 1/6 dilution and centrifuged at 3,000 × g for 10 min. The supernatant was then diluted 1/10 and filtered at 0.45 μm, and three other successive dilutions were done to achieve the following final dilutions: 1/120; 1/1 200; 1/12,000; and 1/120,000. Positive and negative controls (stool samples and media) were tested in parallel to the samples. A neutralizing antibody (Meridian Life Science, Memphis, TN) was used to Ulfy the cytotoxic activity was caused by toxin B. The plate was examined at 24 and 48 h for cell rounding. In terms of analytical sensitivity of the bMx CCNA assay, we have observed high cytotoxic activity using native toxin A at 250 pg/ml, moderate activity at 100 pg/ml, low activity at 20 pg/ml, and no activity at 10 pg/ml. For native purified toxin B the cytotoxic activity was high at 5 pg/ml, moderate at 1.5 pg/ml, low at 0.2 pg/ml, and nonexistent at 0.02 pg/ml.

The differences with the method used at the Leeds Hospital (Leeds CCNA) were the following: the origin of Vero cells (European Collection of Authenticated Cell Cultures, Wiltshire, United Kingdom), the diluent used to dilute the stool sample (phosphate-buffered saline), the preparation of the sample (filtration of sample supernatant), the anti-toxin antibody (C. sordelli antitoxin, Prolab, United Kingdom), and the tested dilutions (1/100 and 1/1,000).

RESULTS

Limits of detection and quantification, repeatability, and reproducibility of SIMOA assays. The toxin A and toxin B concentrations in diluted fecal specimen were determined using calibration curves ranging from 1 to 2,000 pg/ml (Fig. 1). The LOBs obtained with the negative samples were 0.4 and 2.4 pg/ml for toxins A and B, respectively, while the LODs of SIMOA toxin A and toxin B assays were 0.6 and 2.9 pg/ml (Table 1), respectively. LOQ equaled LOD for the toxin B assay, as CVs of samples in this concentration range were below 10%. Intra-assay and interassay CVs for samples above the LOQ were below 10% for the SIMOA assays, except for 1 sample having an interassay CV of 10.4% for the SIMOA toxin A assay and 2 samples having interassay CVs in this concentration range.
of 11.3% and 14% for the SIMOA toxin B assay. Table 2 shows results obtained for 4 representative samples covering the measuring range of the 20 tested.

**Repeatability of sample preparation for toxin detection.** To evaluate the repeatability of the sample preparation method for toxin detection, clinical specimens from different consistencies, ranging from liquid to formed stools, were used. A good repeatability of toxin quantification was observed for all six liquid samples tested (Bristol stool chart type 7). Table 3 shows the results obtained for toxin A (CVs below 10% for the eight independent preparations of each sample). For semiformed (Bristol stool chart types 5 and 6) and formed samples (Bristol stool chart types 1 to 4), four of the six samples tested had a CV of less than 10%. The two formed samples with CVs greater than 10% were classified as hard stool using the Bristol stool chart (type 1 and 2), while the two semiformed samples had a consistency that was difficult to homogenize. The issue of obtained repeatability with these samples was directly correlated to the stool consistency (hard stool or fibrous/filamentous samples) and the difficulty of efficiently homogenizing the sample in the diluent.

**Sensitivity and specificity of SIMOA toxin assays.** The sensitivity and specificity of SIMOA toxin assays were evaluated with clinical samples from 240 patients, consisting of 126 females and 114 males of ages ranging from 7 to 86 years, with a median of 74 years. Using a laboratory case definition, 66 patients were diagnosed with CDI while 174 patients were CDI negative.

Figure 2 shows the ROC curves of the toxin concentration relative to the CDI status of the patients. The areas under the curve (AUC) obtained for SIMOA toxin A and toxin B assays were 0.941 and 0.969, respectively. The selected clinical thresholds were 22.1 and 18.8 pg/ml for toxin A and toxin B, respectively, giving sensitivities of 84.8 and 95.5% and specificities of 83.9 and 83.3% compared to the laboratory case definition (Table 4). By comparison, the *C. difficile* Tox A/B II showed a lower sensitivity of 71.2% and a higher specificity of 95.4% compared to the laboratory case definition. The sensitivity and specificity of the combined SIMOA toxin assays were determined by considering a sample positive if at least one of the two assays gave a positive result. Accordingly, the sensitivity of combined SIMOA assays corresponds to the specificity of the toxin A assay, which has the higher sensitivity of the two. The specificity of the combined assays is lower than the specificity of each assay due to the fact that 8 samples were positive for toxin B only and 7 for toxin A only (Fig. 3).

### TABLE 1

<table>
<thead>
<tr>
<th>Test</th>
<th>LOB (pg/ml)</th>
<th>LOD (pg/ml)</th>
<th>LOQ (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIMOA toxin A</td>
<td>0.4</td>
<td>0.6</td>
<td>1.7</td>
</tr>
<tr>
<td>SIMOA toxin B</td>
<td>2.4</td>
<td>2.9</td>
<td>2.9</td>
</tr>
</tbody>
</table>

LOB, limit of blank; LOD, limit of detection; LOQ, limit of quantification.
The low specificity of both SIMOA assays in comparison to the laboratory case definition is mainly due to the 29 SIMOA toxin-positive results among the 46 GDH- and PCR-positive and CCNA-negative samples (Fig. 3). Some of those samples (n = 8/29; 28%) were also positive by the *C. difficile* Tox A/B II assay. These SIMOA toxin-positive samples were retested inhouse with bMx CCNA and 86% (25/29, Fig. 3) were found positive at a low dilution factor. Discrepancy in the CCNA results between the Leeds laboratory and the bioMérieux inhouse results may be explained by several facts, including the different methods used (cells, antibodies, sample dilution, and neutralizing antibody) and the visual analysis of cytotoxicity. Nevertheless, analysis of discordant results with bMx CCNA showed 11 SIMOA false-positive (toxin A and/or B) results (Fig. 3).

The sensitivity of the SIMOA toxin B assay was higher than the sensitivity of the toxin A assay, as expected, given that the comparison was done with CCNA, an assay more sensitive to toxin B (Table 4). Toxin A was not detected in 10 CCNA-positive samples, while toxin B was not detected in only 3 of these 10 samples (Fig. 3 and 4). Repeat inhouse bMx CCNA for these 3 samples gave a negative result for 2 of them, suggesting a potential degradation of the toxins. By comparison, the *C. difficile* Tox A/B II assay was negative in 19 of the 66 CCNA-positive samples. The SIMOA toxin B assay detected toxins in 84% (16/19) of EIA-negative samples, resulting in 24% (16/66) more samples determined as positive (Fig. 3 and 4).

For a third of the samples, an additional freezing/thawing cycle occurred before testing with the *C. difficile* Tox A/B II assay. Thirteen of the 19 CCNA-positive samples, which got an additional freezing/thawing cycle, gave a positive result with the *C. difficile* Tox A/B II assay, and 6 were found negative, one also being negative with SIMOA. Among the 56 negative samples having an additional freezing/thawing cycle, four gave a positive result with *C. difficile* Tox A/B II assay. These samples were also found positive with the Xpert *C. difficile* assay and inhouse bMx CCNA. The sensitivity and specificity calculated on the 165 samples that did not get an additional freezing/thawing cycle, gave equivalent results to the sensitivity and specificity determined on all the samples (Table 5).

### DISCUSSION

EIAs detecting toxins have been developed to facilitate diagnosis of CDI, but none of the commercially available EIAs has sensitivity equivalent to that of CCNA (13). On the other hand, molecular assays detecting *C. difficile* genes (including toxin genes) have shown higher sensitivity in comparison that of to CCNA but have been criticized for detecting colonized patients having diarrhea for other reasons (15). Furthermore,
work done by Polage et al. and Planche et al. have shown that patients outcome differs according to the testing method. The presence of toxin in the stool strongly correlates with duration of the symptoms and with disease severity, whereas the presence of toxin gene alone did not (12, 22). These results suggest that a sensitive automated assay for the detection and quantification of *C. difficile* toxins in stool could be the most appropriate method for CDI diagnosis. Assays detecting toxins A and B have been recently developed using the SIMOA technology and showed a sensitivity of toxin B assay equivalent to that of CCNA and a specificity close to that of molecular assays and toxigenic culture (20).

We have developed SIMOA toxin A and toxin B assays according to Quanterix methods, using raw materials similar to the ones described by Song et al. (21), and showed that these assays have a better analytical performance than one of the best EIAs commercially available. Our SIMOA toxin A and toxin B assays have LOD of 0.6 and 2.9 pg/ml in pretreated fecal aliquots, respectively, corresponding to 0.013 and 0.061 pg/mg of toxin in original stool samples. These results are slightly different from the ones previously described (LOD, 0.45 and 1.5 pg/ml, corrected for the dilution factor) (21). We believe that this is probably related to the native toxins, which are used as calibrators, and the method used to define these values. Nevertheless, with our clinical cutoffs of 22.1 and 18.8 pg/ml for toxin A and toxin B assays in pretreated samples, we observed similar sensitivity and specificity to the ones published in Song et al. (21), even though the patient populations were not characterized in the same way. In our study, the sensitivity of the SIMOA toxin B assay in comparison to the laboratory case definition was 95.5%, while the sensitivity described by Song et al. (21) was 100% in comparison to that of CCNA. The specificities of our SIMOA toxin A and toxin B assays, compared to that of the Leeds CCNA, were 83.9% and 83.3%, respectively, while Song et al.’s results were 84% and 87%. In both our and Song et al.’s studies, a number of PCR-positive CCNA-negative samples were found positive by the SIMOA toxin assays. Some of the samples also gave a positive result by the *C. difficile* Tox A/B II assay. As previously mentioned by Song et al. (21), this not only brings into question the sensitivity of CCNA, but also the accuracy, reproducibility, and robustness of this poorly

*FIG 2* Receiver operating characteristic (ROC) curves obtained for SIMOA toxin A (A) and toxin B (B) assays. The ROC curves of SIMOA toxin A and toxin B assays are created by plotting the true-positive rate against the false-positive rate at various threshold settings, using the concentration obtained for each pretreated sample and the CDI status of the patient (*n* = 240).

<table>
<thead>
<tr>
<th>Test</th>
<th>Sensitivity (% [95% CI]) (n = 66)</th>
<th>Specificity (% [95% CI]) (n = 174)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIMOA toxin A</td>
<td>84.8 (73.9–92.5)</td>
<td>83.9 (77.6–89)</td>
</tr>
<tr>
<td>SIMOA toxin B</td>
<td>95.5 (87.3–99.1)</td>
<td>83.3 (77–88.6)</td>
</tr>
<tr>
<td>SIMOA toxin A + B</td>
<td>95.5 (87.3–99.1)</td>
<td>79.3 (72.5–85.1)</td>
</tr>
<tr>
<td><em>C. difficile</em> Tox A/B II</td>
<td>71.2 (58.8–81.7)</td>
<td>95.4 (91.1–98)</td>
</tr>
</tbody>
</table>

*Table 4* Sensitivity and specificity of SIMOA toxin assays compared to CDI status

<sup>a</sup>Totals of 66 GDH- and CCNA-positive samples and 174 GDH- and/or CCNA-negative samples. CI, confidence interval.
standardized assay, which can be performed on different cell lines, using various dilutions, and sometimes without antitoxin confirmation. The quantity of toxin measured by SIMOA assay in these samples was low in comparison to the quantity in other CDI patients, also observed by Song et al. The methodology of EIAs and CCNAs are not
TABLE 5 Sensitivity and specificity of SIMOA toxin assays compared to CDI status using samples that did not get an additional freezing/thawing cyclea

<table>
<thead>
<tr>
<th>Test</th>
<th>Sensitivity (% [95% CI]) (n = 47)</th>
<th>Specificity (% [95% CI]) (n = 118)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIMOA toxin A</td>
<td>85.1 (71.7–93.8)</td>
<td>85.6 (77.9–91.4)</td>
</tr>
<tr>
<td>SIMOA toxin B</td>
<td>95.7 (85.5–99.5)</td>
<td>85.6 (77.9–91.4)</td>
</tr>
<tr>
<td>SIMOA toxin A + B</td>
<td>95.7 (85.5–99.5)</td>
<td>80.5 (72.2–87.2)</td>
</tr>
<tr>
<td>C. difficile Tox A/B II</td>
<td>72.3 (57.4–84.4)</td>
<td>96.6 (91.5–99.1)</td>
</tr>
</tbody>
</table>

aTotals of 47 GDH- and CCNA-positive samples and 118 GDH- and/or CCNA-negative samples.

the same. Detection of C. difficile toxin B presence is physically determined by EIA, whereas CCNA results demonstrate the results of toxin B activity. One potential explanation for the SIMOA-positive CCNA-negative samples may be the preanalytical loss of toxin B activity, whereas toxins remain detectable by immunoassay.

At this time, we do not understand the true meaning for patients when a low toxin concentration is detected. Highly sensitive toxin assays may suffer from the same specificity problem as highly sensitive molecular tests, which can lead to the erroneous identification of uninfected individuals as CDI patients (23). Since it is considered unnecessary to treat colonized patients (24), we face a clinical quandary about how to manage individuals with low fecal toxin concentrations—are they colonized or infected? Whether we can distinguish infected and colonized patients with SIMOA C. difficile toxin assays, based on toxin concentrations, is currently unknown. Additional epidemiologic and interventional studies are required to answer this question.

The limits of our study are the lack of clinical confirmation of CDI status, the number of samples tested, the comparison to other EIAs detecting toxins, and the fact that an additional freezing/thawing cycle occurred for some samples prior to testing with the C. difficile Tox A/B II assay. It is known that a freezing/thawing cycle is not recommended for toxin stability. Nevertheless, it is important to point out that toxins were detected by C. difficile Tox A/B II assay in samples that had an additional freezing/thawing cycle, and that the sensitivity and specificity values were not different without these samples. Finally, clinical correlation studies of CDI presentation and outcome with a large number of samples will be required for determination of the diagnostic accuracy of these assays.

In our comparison of the SIMOA assays and the C. difficile Tox A/B II assay, we observed that the SIMOA toxin A and toxin B assays have higher sensitivities than the C. difficile Tox A/B II assay (84.8 and 95.5% versus 71.2%). The use of the SIMOA assays allowed the detection of toxin-positive samples that would have been missed by the commercial EIA. In comparison to the analytical sensitivity of EIAs determined in diluted supernatant (without correction by dilution factor), we described a LOD of toxin B of 2.9 pg/ml, corresponding to 0.061 pg/mg of toxin in the stool. Hence, C. difficile toxin detection using SIMOA technology has the potential to improve CDI diagnosis. The SIMOA assay could replace current EIAs for laboratories that do not have the skills and capacity to perform CCNA and would increase the specificity of positive results compared with that of current molecular tests.

ACKNOWLEDGMENTS

We thank Laure Allard and Sandrine Maitre (bioMérieux) for their help in estimating LOD and LOQ. We thank Quanterix for sharing with us their expertise in SIMOA technology.

A.B., A.L., B.R., and A.F. are employees of bioMérieux. M.M. is an employee of bioMérieux since 2012 and received research funding from bioMérieux prior to that.

M.W. has received consulting fees from Actelion, Astellas, bioMérieux, Cambimune, Da Volterra, Ferring, MedImmune, Menarini, Merck, Meridian, Pfizer, Qiagen, Sanofi-Pasteur, Seres, Summit, Synthetic Biologics, and Valneva; lecture fees from Alere, Astellas, Merck, and Pfizer; and grant support from Actelion, Astellas, bioMérieux, Da Volterra, Merck, Pfizer, Sanofi-Pasteur, Seres, and Summit.

TABLE 5 Sensitivity and specificity of SIMOA toxin assays compared to CDI status using samples that did not get an additional freezing/thawing cyclea
REFERENCES